PamBio Overview

  • Founded
  • 2014

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

PamBio General Information


Developer of drug therapy intended to treat acute bleeding conditions. The company's therapy helps in stabilizing blood clots, increasing anti-bleeding treatment time-window beyond 3 hours, minimizing blood toxicity in the brain and has reduced side effects, enabling physicians to treat their patients in an enhanced way.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • NGT3 VC Technological Incubator
  • P.O. Box 1252
  • Nof HaGalil 17111
  • Israel
+972 00-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PamBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 01-May-2017 0000 Completed Out of Business
2. Angel (individual) 18-Jul-2016 000 0000 Completed Startup
1. Accelerator/Incubator $3M $3M Completed Startup
To view PamBio’s complete valuation and funding history, request access »

PamBio Executive Team (4)

Name Title Board Seat Contact Info
Amos Ofer Ph.D Chief Executive Officer
Abd Higazi MD Co-Founder & Chief Scientific Officer
Nuha Higazi Ph.D Co-Founder & Chief Technology Officer
You’re viewing 3 of 4 executive team members. Get the full list »

PamBio Board Members (3)

Name Representing Role Since
Noa Shelach Ph.D PamBio Board Member 000 0000
You’re viewing 1 of 3 board members. Get the full list »